comparemela.com
Latest Breaking News On - Nivolumab plus talazoparib - Page 1 : comparemela.com
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Ohio
United-states
James-isaacs
Department-of-hematology
Medical-oncology
Cleveland-clinic
Cleveland-clinic-gross-family-melanoma-registry
Nivolumab
Talazoparib
Opdivo
Talzenna
Nivolumab-plus-talazoparib
vimarsana © 2020. All Rights Reserved.